Moreover, approximately 40% of ERα-positive breast cancer patients have high levels of ER-α36 in their tumors, and this subset of patients are less likely to receive benefits from tamoxifen therapy compared to those with ERα-positive/ER-α36-negative tumors [5]. Here, ESR1 is linked to breast cancer.